Business
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology
About this update from Novocure Limited
[{"type":"text","content":" ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target tumor during treatment.\n\n\nHighlights of Novocure’s poster presentations include:\n\n\n\na new process to identify optimized, personalized TTFields array layouts for each patient with glioblastoma (GBM) using segmentation-based treatment planning (SBTP) software\n\n\n\n\n\nretrospective, simulated testing of SBTP to compare outputs from array layouts generated with SBTP versus array layouts generated with NovoTAL, the current standard treatment planning software, with results suggesting that SBTP-generated layouts meet established treatment thresholds for TTFields therapy, and could potentially lead to improved clinical outcomes for patients with GBM\n\n\n\n\n\na simulation study evaluating the effects of body mass index (BMI) on field intensities delivered to the lungs with TTFields therapy. Results support the feasibility of TTFields therapy delivery to the lungs regardless of BMI and highlight the importance of choosing the appropriate array size for each patient.\n\n\n\n“We are committed to continuous innovation, and we look forward to sharing new insights about the use of TTFields therapy with the scientific community,” said Pritesh Shah, Novocure’s Chief Growth Officer. “By developing segmentation-based treatment planning software to optimize array placement and exploring how factors such as array size affect the delivery of TTFields therapy, we aim to advance our therapy as we pursue our mission to extend survival in some of the most aggressive forms of cancer.”\n\n\nPresentations on TTFields at the 2023 ASTRO Annual Meeting will include:\n\n\n\nThe Effect of Body Mass Index on Tumor Treating Fields (TTFields) Intensity Distribution in the Lungs. Presenter: Nadav Shapira. 4:45 p.m. – 6 p.m. PT on Sunday, Oct. 1.\n\n\n\n\n\nPatient-Specific Segmentation-Based Treatment Planning vs. NovoTAL for TTFields Therapy in Glioblastoma. Presenter: Brian Berger. 10:45 a.m. – 12 p.m. PT on Monday, Oct. 2.\...